Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer

To evaluate focal high dose rate (HDR) brachytherapy in locally recurrent prostate cancer.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research

Related Links:

To validate the 2019 NCCN subgroups of favorable- and unfavorable-intermediate risk (IR) prostate cancer among patients treated with brachytherapy, who are underrepresented in the studies used to develop the 2019 NCCN classification.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
The management of high-risk prostate cancer is challenging, as patients have a high risk of both local and distant relapse. Although adjuvant systemic treatment remains an important component of management, for those receiving radiotherapy, optimal local treatment should include a brachytherapy boost. This may be given by low dose rate (LDR) or high dose rate (HDR) techniques, but HDR has several advantages over LDR by virtue of more consistent dose optimisation, ability to treat outside the prostate and lower toxicity.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Overview Source Type: research
We present a narrative review regarding recent advances in understanding regarding comparisons of overall and PCa-specific mortality measures among patients with high-risk PCa treated with either an RP/adjuvant RT or an RT/ADT approach. We give special consideration to recent trends toward the assembly of multi-institutional series targeted at providing high-quality data to minimize the effects of residual confounding. We also provide a narrative review of recent studies examining brachytherapy boost and systemic therapies, as well as an overview of currently planned and ongoing studies that will further elucidate strategi...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract OBJECTIVES: A cohort of HDR monotherapy patients was analysed to (i) establish the frequency of non-malignant urethral stricture; (ii) explore the relation between stricture formation with the dose distribution along the length of the urethra, and MRI radiomics features of the prostate gland. METHODS: A retrospective review of treatment records of patients who received 19 Gy single fraction of HDR BT was carried out. A matched pair analysis used one control for each stricture case matched with pre-treatment IPSS score, number of needles used and clinical target volume (CTV) volume for each str...
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
Conclusions: Combination treatment with celecoxib and tamsulosin during the peri-operative period is not warranted for improving QoL in patients undergoing LDR brachytherapy. PMID: 31749848 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Authors: Barnes JM, Gabani P, Sanders M, Chundury A, Altman M, Garcia-Ramirez J, Li H, Zoberi JE, Baumann BC, Gay HA Abstract Purpose: High-dose-rate brachytherapy (HDR-BT) delivered in a single fraction as monotherapy is a potential treatment modality for low- and intermediate-risk prostate cancer (LIR-PC); however, outcome data with this technique remain limited. Here we describe our institutional HDR monotherapy experience and report the efficacy and toxicity of this treatment. Material and methods: LIR-PC patients who received a definitive single fraction HDR-BT during 2013-2017 were retrospectively identif...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Promoting prostate HDR in US would not be bad. scarbrtj said: In theory based on this chart could single fraction prostate HDR pay $23K global? If so look out for a prostate HDR renaissance in the US. CMS is, wittingly or unwittingly, massively incentivizing (and disincentivizing) certain treatment paradigms with this new model. For better or worse! Click to expand...
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums
Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease. PET radiotracers targeting PSMA such as 18F-DCFPyL have shown promise in restaging men with recurrent disease post-prostatectomy but are less well characterized in the setting of radio-recurrent disease.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Conclusion: LDR-EBRT may provide more effective PSA control at 5 years compared with HDR-EBRT. Direct comparison of these treatments through randomised trials are recommended to investigate this hypothesis further. PMID: 31701035 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Radiat Oncol Source Type: research
AbstractProstate cancer is the most common cancer among men in the USA. Interestingly, recent studies suggest that patients with inflammatory bowel disease (IBD) are at increased risk of developing prostate cancer. Importantly, patients with IBD who develop prostate cancer require thoughtful care when using immunosuppressants to treat the IBD in the setting of malignancy. Further, consideration must be given to the proximity of the prostate to the gastrointestinal tract when treating with radiation where there is concern for the effects of inadvertent exposure of radiation to the diseased bowel. In general, management of i...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Prostate Cancer | Radiology